A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered GB1211 in Participants With Suspected or Confirmed Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis

Phase 1

Withdrawn

• Conditions: Non-alcoholic Steatohepatitis (NASH)
• Interventions: Drug: Placebo; Drug: GB1211

• Registration Number: NCT04607655
• Lead Sponsor: Galecto Biotech AB

Brief Summary

This study is a randomised, double-blind, placebo controlled, phase Ib trial in subjects with suspected or confirmed non-alcoholic steatohepatitis (NASH) and liver fibrosis

Detailed Description

This study is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered GB1211 a gelectin-3 inhibitor over 12 weeks. Participants will receive two doses of GB1211, each given twice per day and compared to placebo in participants with fibrotic NASH

Study Timeline

• Status Verified: 2020-10
• Study First Submitted: 2020-10-19
• Study First Submitted QC: 2020-10-23
• Study First Posted: 2020-10-29
• Last Update Submitted: 2021-02-02
• Last Update Posted: 2021-02-04
• Study Start: 2021-03
• Primary Completion: 2022-07
• Study Completion: 2022-07

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. Males or females, of any race, ≥ 18 and ≤ 75 years of age at enrolment. 2. Body mass index (BMI) of ≥ 25.0 and ≤45.0 kg/m2 3. Diagnosis of suspected NASH and liver fibrosis (Chalasani et al. 2012):

a. Evidence of hepatic steatosis within the 24 weeks prior to Screening: i. magnetic resonance imaging (MRI PDFF) suggesting liver fat ≥ 8% or ii. ultrasound (US) indicating fatty liver or iii. FibroScan Controlled Attenuation Parameter (CAP) > 270 dB/m. iv. in participants without a documented history of fatty liver, a FibroScan CAP or US can be performed at Screening. Participants with FibroScan CAP > 270 dB/m or US indicating fatty liver are eligible AND b. Metabolic risk factors: i. Metabolic syndrome (Adult Treatment Panel III definition) requires three or more of the following five disorders (Grundy et al. 2005):

1. elevated waist circumference (≥102 cm in men and ≥88 cm in women),

2. hypertriglyceridemia (≥1.7 mmol/l),

3. low HDL cholesterol level (<1.03 mmol/l in men and <1.3 mmol/l in women),

4. high blood pressure (systolic blood pressure ≥130 mmHg and/or diastolic blood pressure ≥85 mmHg and/or pharmacological treatment)

5. elevated fasting glucose (≥5.6 mmol/l and/or pharmacological treatment) ii. OR T2DM (defined as stable diabetes with glycosylated haemoglobin [HbA1c] ≤ 9.5%) OR A diagnosis of confirmed NASH and liver fibrosis based on a biopsy within 12-months of Screening

6. Liver stiffness as measured by transient elastography (FibroScan) ≥ 8.5 KPa 5. Women of non-childbearing potential defined as permanently sterile (see Appendix 4) or postmenopausal (see Appendix 4) or Women considered to be of childbearing potential who agree to use highly effective birth control methods until 90 days after the Follow-up visit (see Appendix 4) 6. Males will agree to use contraception throughout the study and until 90-days after the Follow-up visit 7. Male participants must agree to refrain from sperm donation and females should refrain from ova donation from the date of Randomisation (Day -1) until 90 days after the Follow up visit 8. Able to comprehend and willing to sign an ICF and to abide by the study restrictions

Exclusion Criteria

1. Any other causes for secondary hepatic fat accumulation such as significant alcohol consumption, use of steatogenic medication or hereditary disorders

2. The following clinical laboratory results at Screening:

   1. ALT > 200 U/L
   2. AST > 200 U/L

3. History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy, cholecystectomy, and hernia repair will be allowed)

4. Positive alcohol breath test result or positive urine drug screen (confirmed by repeat) at Screening or Randomisation

5. Positive hepatitis panel and/or positive HIV test

6. Evidence of acute Hepatitis A virus (HAV) and a positive serological test for anti-HAV IgM antibodies

7. Estimated glomerular filtration rate (eGFR) < 60 mL/[min*1.73 m²] at Screening

8. Use or intend to use slow release medications/products considered to still be active within 14 days prior to Randomisation, unless deemed acceptable by the Investigator (or Designee)

9. Participant taking any antidiabetic medications, with the exception of metformin and sulfonylureas within 3 months prior to Screening

10. Have previously completed or withdrawn from this study investigating GB1211 and have previously received the investigational product

11. Participant who, in the opinion of the Investigator (or Designee), should not participate in this study

12. Vulnerable/institutionalised patients

13. Patients related to PI/site staff

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Oral GB1211, Placebo, twice a day	Placebo	Placebo is administered as inhalation once a day
Oral GB1211, 100 mg, twice a day	GB1211	GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day.
Oral GB1211, 10 mg, twice a day	GB1211	GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day.

Primary Outcome Measures

Name	Time	Method
Safety and Tolerability of GB1211	12 Weeks	Physical examination abnormalities measured by vital signs and 12 lead ECG

Secondary Outcome Measures

Name	Time	Method
Pharmacokinetics of GB1211	12 Weeks	Volume of distribution and rate of elimination